Sutro Biopharma, Inc.
NASDAQ:STROBiotechnology
+$0.32 today
- Market cap
- $141.11M
- Beta
- 1.55
- P/E (TTM)
- -0.0
- EPS (TTM)
- -$1,174.12
Volume 0.31M
Average 0.28M
STRO Net Receivables
Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.
Sutro Biopharma, Inc.NASDAQ: STRO
Net Receivables · Q1 FY2026 · quarter ended Mar 2026
Net receivables falls 7.9% from a year ago
Net receivables stood at $12.48M at the end of Q1 FY2026, down 7.9% from a year earlier and up 213.9% from the prior quarter. Over 3 fiscal years it compounded at -17.7% a year.
Context
- Net receivables amounted to 5.2% of total assets at the end of Q1 FY2026, up 0.9 pp from a year earlier.
- Net receivables increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether net receivables keeps falling in the next quarterly balance sheet after a -7.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Receivables history
USD · from the balance sheet
- Latest · FY2025
- 3.98M USD
- Year-over-year change
- -53.8%
- 4-year CAGR
- -24.8%
| Period | Period end | Net Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.98M | -53.8% |
| FY2024 | 2024-12-31 | 8.62M | -76.1% |
| FY2023 | 2023-12-31 | 36.08M | +406.6% |
| FY2022 | 2022-12-31 | 7.12M | -42.8% |
| FY2021 | 2021-12-31 | 12.45M | — |
Net Receivables vs competitors
How STRO compares with its peers on the latest reported figures
- Peers report in different currencies, so net receivables is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -7.9% is the 3rd highest of 6, against a peer median of -42.0%.
- Net receivables amounts to 5.2% of total assets for STRO, versus a peer median of 0.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $12.48M USD | -7.9% | -17.7% | 5.2% | |
| Mar 2026 | $4M USD | +99900.0% | — | 2.8% | |
| Mar 2026 | €1.65M EUR | -2.4% | -0.1% | 3.4% | |
| Mar 2026 | $914K USD | -45.7% | -36.0% | 0.5% | |
ARTVArtiva Biotherapeutics, Inc. | Mar 2026 | $600K USD | -42.0% | +13.5% | 0.6% |
| Dec 2025 | $161K USD | -84.7% | -11.5% | 0.3% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
KLRSKalaris Therapeutics Inc | Mar 2026 | $0 USD | — | — | 0.0% |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding STRO) | — | -42.0% | -5.8% | 0.4% | |
Competitors are the stored peer set for STRO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 30.41M | 47.25M | 69.27M | 190.3M | 58.13M |
| Short-term Investments | 167.52M | 287.11M | 306.35M | 126.59M | 83.3M |
| Net Receivables | 12.45M | 7.12M | 36.08M | 8.62M | 3.98M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 1 | 11.67M | 9.85M | 17.8M | 5.52M |
| Total Current Assets | 218.52M | 353.15M | 421.54M | 343.31M | 150.93M |
| Property, Plant & Equipment (Net) | 51.59M | 51.06M | 44.76M | 35.87M | 21.55M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 68.78M | (32.02M) | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 2.53M | 34.75M | 4.44M | 8.03M | 1.35M |
| Total Non-current Assets | 122.89M | 53.79M | 49.19M | 43.9M | 22.9M |
| Total Assets | 341.41M | 406.94M | 470.74M | 387.21M | 173.83M |
| Account Payables | 6.01M | 4.8M | 9.44M | 10.48M | 7.57M |
| Short-term Debt | 9.38M | 17.09M | 4.06M | 0 | 0 |
| Tax Payables | 0 | 0 | 15.17M | 18K | 0 |
| Deferred Revenue | 5.5M | 16.76M | 20.67M | 69.78M | 10.56M |
| Other Current Liabilities | 11.42M | 11.64M | 18.58M | 16.91M | 17.56M |
| Total Current Liabilities | 41.74M | 66.55M | 93.75M | 131.89M | 75.13M |
| Long-term Debt | 15.74M | 3.77M | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 89.89M | 202.49M | 193.35M | 221.56M |
| Other Non-current Liabilities | 146K | 119K | 1.69M | 1.69M | 1.69M |
| Total Non-current Liabilities | 47.11M | 123.35M | 227.34M | 210.71M | 231.15M |
| Total Liabilities | 88.84M | 189.9M | 321.09M | 342.61M | 306.28M |
| Common Stock | 46K | 58K | 61K | 83K | 9K |
| Retained Earnings | (333.41M) | (452.62M) | (559.41M) | (786.87M) | (977.96M) |
| Accumulated OCI | (314K) | (618K) | 21K | 39K | 19K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 252.56M | 217.05M | 149.65M | 44.6M | (132.45M) |
| Total Debt | 57.37M | 55.02M | 33.64M | 23.15M | 15.67M |
| Net Debt | 26.96M | 7.76M | (35.63M) | (167.15M) | (42.46M) |
Sutro Biopharma, Inc.
NASDAQ:STRO
Intrinsic Alpha fair value
Locked
Current Price
$8.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.